By Denny Jacob
Theseus Pharmaceuticals reduced its workforce by 72%, part of its exploration of strategic alternatives aimed at maximizing shareholder value. The clinical-stage biopharmaceutical company said it will consider a range of options including a potential sale of assets, a sale of the company, a merger or other strategic action. Shares surge 34% in after-market trading.
Electric-vehicle startup Fisker missed analysts’ expectations for revenue and losses in the third quarter. Shares retreat 14% in post-market trading.
Marpai suspended further financial guidance for full-year 2023 operating results and won’t provide specific financial guidance moving forward. Shares decline 7% in after-market trading.
Write to Denny Jacob at [email protected]
Read the full article here
